Literature DB >> 21945962

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

Dai Wang1, Fengsheng Li, Daniel C Freed, Adam C Finnefrock, Aimin Tang, Shannon N Grimes, Danilo R Casimiro, Tong-Ming Fu.   

Abstract

Naturally acquired immunity significantly reduces the risk of congenital cytomegalovirus (CMV) infection in future pregnancies. An immune response comparable to that of natural infection has been used as a benchmark for CMV vaccine efficacy; however, the magnitude and persistence of the neutralizing antibody responses in naturally infected women are not completely understood. In this study, we quantitatively analyzed a panel of 375 female CMV convalescent sera ranging in age from 18 to 84 years, for its ability to block virus entry into epithelial cells and fibroblasts, as well as its binding potential to CMV particles. The geometric mean titer of the sera in this panel to neutralize 50% of the virus entry into epithelial cells was 7491, compared to 802 for entry into fibroblasts. The epithelial neutralizing titers were statistically indistinguishable among different age groups, and conformed to a normal distribution. There was a weak correlation between the levels of neutralization and the binding activities to viral particles. Our data confirmed that natural CMV infection in healthy women induces potent neutralizing antibodies against infection of both fibroblasts and epithelial cells. The serum neutralizing activities were maintained at high levels throughout the child bearing age. The corresponding titers may serve as a biomarker for CMV vaccine efficacy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945962     DOI: 10.1016/j.vaccine.2011.09.056

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.

Authors:  Ravit Arav-Boger; Sallie R Permar; Cody S Nelson; Diana Vera Cruz; Melody Su; Guanhua Xie; Nathan Vandergrift; Robert F Pass; Michael Forman; Marie Diener-West; Katia Koelle
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

2.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Martin Zydek; Lenore Pereira
Journal:  Am J Pathol       Date:  2016-09-13       Impact factor: 4.307

4.  Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition.

Authors:  Frances M Saccoccio; Jennifer A Jenks; Hannah L Itell; Shuk Hang Li; Madison Berry; Justin Pollara; Corey Casper; Soren Gantt; Sallie R Permar
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

5.  In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

Authors:  Hetalkumar D Patel; Pavel Nikitin; Thomas Gesner; James J Lin; David T Barkan; Claudio Ciferri; Andrea Carfi; Tahmineh Akbarnejad Yazdi; Peter Skewes-Cox; Brigitte Wiedmann; Nadine Jarousse; Weidong Zhong; Adam Feire; Christy M Hebner
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.

Authors:  Julie H Ishida; Tracy Burgess; Michael A Derby; Pearline A Brown; Mauricio Maia; Rong Deng; Brinda Emu; Becket Feierbach; Ashley E Fouts; X Charlene Liao; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

7.  Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Authors:  Xiaohong Cui; Daniel C Freed; Dai Wang; Ping Qiu; Fengsheng Li; Tong-Ming Fu; Lawrence M Kauvar; Michael A McVoy
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

8.  Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Authors:  Daniel C Freed; Qi Tang; Aimin Tang; Fengsheng Li; Xi He; Zhao Huang; Weixu Meng; Lin Xia; Adam C Finnefrock; Eberhard Durr; Amy S Espeseth; Danilo R Casimiro; Ningyan Zhang; John W Shiver; Dai Wang; Zhiqiang An; Tong-Ming Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

Authors:  Devon J Shedlock; Kendra T Talbott; Stephan J Wu; Christine M Wilson; Karuppiah Muthumani; Jean D Boyer; Niranjan Y Sardesai; Sita Awasthi; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

10.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.